NCT06348706View on ClinicalTrials.gov

Effect of Dipeptidyl Peptidase- 4 Inhibitors on Non-Alcoholic Steatohepatitis and Type 1 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 10, 2022

Primary Completion Date

December 1, 2023

Study Completion Date

January 15, 2024

Conditions
Diabetes Mellitus, Type 1NASH
Interventions
DRUG

Dipeptidyl peptidase 4 (DPP-4) inhibitor

Intervention group received Dipeptidyl peptidase-4 (DPP-4) inhibitors supplementation in a dose of 50 mg with main meal for 6 months.

Trial Locations (1)

11361

Nancy Elbarbary, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER